抽象的
长效的β2-肾上腺素能受精剂,如Salmeterol,减少了至少12小时的气道反应性,但这种效果似乎随着定期使用而降低。我们评估了Salmeterol对甲素诱导的支气管混合物对甲素诱导的支气管混合物的时间过程,其吸入皮质类固醇(IC)的调节及其对哮喘控制的影响。根据其药物需求分为两组,将三十二个受试者(13名男性和19名女性)分为两组:支气管扩张剂(Bd)单独(n = 16)或IC(n = 16)。经过2周的运行期后,进行了双盲交叉研究。来自两组的受试者接受了Salmeterol 50 microg B.I.D.或安慰剂,每次以随机顺序排列,分开2周的洗涤期。在每次治疗期之前和之后,在吸入萨尔梅勒或安慰剂之前和1和12小时之前和之后,在每次治疗期之前和之后测量甲素溶液在一秒钟(PC20)中均落入强制呼气体积。在第一个剂量和4周后,在萨尔梅洛尔后,一秒钟(FEV1)中的基线强制呼气量(FEV1)显着增加(BD组:19和17%; IC:22和13%)。在给药的第一天,Salmeterol分别在BD组中分别在BD组和1至12小时的PC20和1和12 H之前提供了显着的2.2,21.7和12.4,Mg x ml(-1)的群体的显着保护2.1,11.6和55mg x ml(-1)分别在ICS组中。 After 4 weeks, this effect was significantly attenuated in both groups with a PC20 before, 1 and 12 h postdose of 3.3, 10.9 and 7.1 mg x mL(-1), respectively, in the BD group and 2.1, 5.0 and 2.3 mg x mL(-1), respectively, in the ICS group. This loss of protective effect was of similar magnitude in both groups. Respiratory symptoms, rescue beta2-agonist use and baseline FEV1 did not change significantly throughout the study in both groups. In conclusion, the bronchoprotective effect of salmeterol decreased with regular use both 1 and 12 h postdose; inhaled corticosteroids did not prevent this reduction. However, the development of tolerance was not associated with loss of asthma control.